iSpecimen Inc. Share Price

ISPC

US45032V3069

Software

Market Closed - Nasdaq 20:00:00 30/10/2026 GMT			5-day change	1st Jan Change
0.8255 ^USD	+4.19%		+1.04%	-92.07%

09-03	ISpecimen Inc. entered into an asset purchase agreement to acquire certain artificial intelligence software, intellectual property and related assets of Foldlab AI Ltd from Foldlab AI Ltd. for $4.5 million.	CI
08-31	ISpecimen Inc. Announces CEO Changes	CI

Analysts' recommendations: iSpecimen Inc.

23/09/22	EF Hutton Trims iSpecimen's Price Target to $4.25 From $5.50, Maintains Buy Rating	MT
04/01/22	Craig-Hallum Initiates iSpecimen at Buy Rating With $20 Price Target	MT

More recommendations

Press Releases: iSpecimen Inc.

10-29	ISpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent	NE
09-29	ISpecimen Supports Hospital Validation of New Chemistry Analyzer	NE
08-20	ISpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks	NE
08-07	ISpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants	AQ
08-07	E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen	AQ

More press releases

Managers and Directors: iSpecimen Inc.

Manager	Title	Age	Since
Shahin Behroyan CEO	Chief Executive Officer	39	25/08/2026
Yu Ying Liang DFI	Director of Finance/CFO	36	12/12/2024
Katharyn Field CEO	Chief Executive Officer	32	06/11/2025

Director	Title	Age	Since
Avtar Dhaliwal BRD	Director/Board Member	31	24/09/2024
Anthony Lau BRD	Director/Board Member	41	19/06/2025
Arphing Lee BRD	Director/Board Member	35	06/11/2025

More insiders

iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Companyâ€™s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.

Employees

Sector

Software

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	US$0.8255	+4.19%	543,341
29/10/26	US$0.7923	-9.35%	2,593,803
28/10/26	US$0.8740	+0.22%	30,648
27/10/26	US$0.8721	+3.85%	49,117
26/10/26	US$0.8398	+2.79%	66,415

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - iSpecimen Inc.

Company calendar

Market Cap	2.08M 1.86M 1.71M 1.55M 2.9M 197M 2.96M 20.43M 8.2M 104M 7.8M 7.64M 327M	P/E 2024	-0.15x	P/E 2025	-0.11x
Enterprise Value	-4.53M -4.06M -3.73M -3.38M -6.32M -430M -6.44M -44.53M -17.88M -226M -17.01M -16.65M -714M	EV / Sales 2024	0.11x	EV / Sales 2025	-2.11x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

09-03	ISpecimen Inc. entered into an asset purchase agreement to acquire certain artificial intelligence software, intellectual property and related assets of Foldlab AI Ltd from Foldlab AI Ltd. for $4.5 million.	CI
08-31	ISpecimen Inc. Announces CEO Changes	CI
08-21	Top Premarket Decliners	MT
08-20	Ispecimen Inc. Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks	CI
08-14	ISpecimen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-07	ISpecimen Closes $5 Million Public Offering of Common Stock, Warrants	MT
05-18	ISpecimen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-10	ISpecimen Inc. announced that it has received $2.500004 million in funding	CI
05-07	ISpecimen Inc. announced that it expects to receive $2.499999 million in funding	CI
04-13	Ispecimen Inc - annual meeting repeatedly adjourned for lack of quorum - SEC filing	RE
04-01	ISpecimen Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-31	ISpecimen Inc. Auditor Raises 'Going Concern' Doubt	CI
03-13	Wall Street Set to Open Higher Friday as Investors Parse Inflation Data, Oil Prices	MT

1 day	+4.19%
1 week	+1.04%
Current month	-30.04%
1 month	-30.04%
3 months	-54.89%
6 months	-84.22%
Current year	-92.07%

1 week	0.75	0.94
1 month	0.75	1.15
Current year	0.75	18
1 year	0.75	32.96
3 years	0.75	584
5 years	0.75	23,183.92
10 years	0.75	23,183.92

Date	Insider	Type	Main position	Quantity	% Market Cap.
25/09/24	Katharyn Field	Free	Chief Executive Officer	168	0.0013%
25/09/24	Richard Paolone	Free	Chairman	168	0.0013%
25/09/24	Avtar Dhaliwal	Free	Director	168	0.0013%

iSpecimen Inc. Share Price

Stocks

ISPC

US45032V3069

Software

Valuation: iSpecimen Inc.

Chart: iSpecimen Inc.

Latest news: iSpecimen Inc.

Analysts' recommendations: iSpecimen Inc.

Press Releases: iSpecimen Inc.

Quotes and Performance

Price Extremes

Managers and Directors: iSpecimen Inc.

Latest insider transactions

Other Software

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ISPECIMEN INC.	+4.19%	+1.04%	-97.34%	-99.84%	2.08M
MICROSOFT CORPORATION	-1.55%	-0.50%	-0.73%	+54.73%	3,876B
PALANTIR TECHNOLOGIES INC.	-6.27%	-6.42%	-5.37%	+1,153.30%	442B
ORACLE CORPORATION	-6.37%	+3.57%	-49.13%	+28.55%	396B
PALO ALTO NETWORKS, INC.	-3.86%	-3.86%	+67.62%	+206.74%	300B
SAP SE	+1.12%	-1.47%	-6.46%	+68.19%	272B
CROWDSTRIKE HOLDINGS, INC.	-4.10%	-2.77%	+85.96%	+473.69%	257B
SERVICENOW, INC.	-4.15%	-33.87%	-43.77%	-7.55%	109B
FORTINET, INC.	-2.17%	-24.40%	+61.62%	+141.62%	99.98B
ADOBE INC.	+0.85%	-5.15%	-26.24%	-52.51%	97.39B
Average	-0.23%	-7.38%	-1.38%	+196.69%	584.96B
Weighted average by Cap.	+0.21%	-2.10%	+2.52%	+161.40%

	2024	2025
Net sales	9.29M 8.32M 7.65M 6.94M 12.96M 882M 13.21M 91.28M 36.64M 464M 34.87M 34.13M 1.46B	1.93M 1.73M 1.59M 1.44M 2.69M 183M 2.74M 18.95M 7.61M 96.35M 7.24M 7.09M 304M
Net income	-12.5M -11.19M -10.3M -9.33M -17.44M -1.19B -17.76M -123M -49.29M -624M -46.9M -45.91M -1.97B	-10.49M -9.39M -8.64M -7.83M -14.63M -996M -14.91M -103M -41.36M -524M -39.36M -38.52M -1.65B
Net Debt	-1.57M -1.4M -1.29M -1.17M -2.19M -149M -2.23M -15.39M -6.18M -78.23M -5.88M -5.75M -247M	-6.61M -5.92M -5.45M -4.94M -9.23M -628M -9.4M -64.96M -26.08M -330M -24.81M -24.29M -1.04B

Markets		Quality
Nasdaq	ISPC	Delayed
CBOE	ISPC	Real-time